Friday, July 10, 2026

Drug profile · INN

reteplase

reteplase (ECOKINASE) is a tissue-type plasminogen activator exogenous protein. Current US regulatory status: approved.

FDA: approved EMA: withdrawn Blood and blood forming organs (B01) B01AD07
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — reteplase
US status
approved
Class
Blood and blood forming organs (B01)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

reteplase (ECOKINASE) is a tissue-type plasminogen activator exogenous protein. Current US regulatory status: approved.

Key facts

INN reteplase
Brand ECOKINASE
Mechanism Tissue-type plasminogen activator exogenous protein
Target Tissue-type plasminogen activator
Therapeutic class Blood and blood forming organs (B01)
Formulation VIAL
ATC code B01AD07

Mechanism of action

Tissue-type plasminogen activator exogenous protein

Primary target: Tissue-type plasminogen activator

Approval history

Authority Status Date
FDA approved
EMA withdrawn

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is reteplase?

reteplase (ECOKINASE) is a tissue-type plasminogen activator exogenous protein. Current US regulatory status: approved.

What is the brand name for reteplase?

ECOKINASE is a marketed brand name for reteplase. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of reteplase?

reteplase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.